Are Peptides Legal Now? The Reported 'Temporary Sale' Plan, Checked Against the Record
The short version
- Update, 20 October: the plan now has an official trace. On 14 October the FDA sent an action titled "Interim Access Policy for Compounding Using Certain Peptides" to White House review; its text and the peptides it covers are still unpublished. Details: our piece on the White House filing.
- No federal document has changed the legal status of any peptide. The Federal Register has no FDA notice mentioning peptides since 15 September, checked on 14 October.
- The 'temporary sale' plan comes from a Washington Post report of 7 October citing two unnamed people. It has not been announced, the peptides are not named, and the timing is unclear.
- As reported, it would run through state-licensed compounding pharmacies and prescriptions. Nothing reported would let research-use-only vendors sell peptides for human use.
- FDA drug center staff oppose it, according to Pink Sheet (8 October). KFF Health News reported on 13 October that the FDA has yet to issue a final decision on the six peptides its advisers backed in July.
- We will update this page the day an order, notice or guidance is published.
Since 7 October, search results and social posts have been saying that peptides are about to become legal, or already are. The claim traces back to one report: a Washington Post exclusive that the Trump administration is crafting plans that would "allow the temporary sale of certain previously restricted peptides" while new rules are written. This piece sets out what that report says, what the official record says as of 14 October 2026, and where the gap between the two is.
What was reported
The Washington Post story, by Rachel Roubein, opens: "The Trump administration is crafting plans that would allow the temporary sale of certain previously restricted peptides as federal health officials hammer out new regulations around the controversial products, according to two people familiar with the matter who spoke on the condition of anonymity to share private details."
The same report, in its syndicated text, says such a move "would allow some compounding pharmacies to dispense certain peptides", that "the plan has not yet been announced and timing was unclear, meaning it could still change", that "the Department of Health and Human Services did not comment", and that "it was not immediately clear which peptides the administration is aiming to make temporarily available".
The one mechanism named in the story comes from the compounding industry. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, told the Post his group has asked the FDA to use interim enforcement discretion, meaning the agency would focus its enforcement on other matters, "to let state-licensed compounding pharmacies prepare the drugs for patients with a prescription", with conditions including enhanced disclosures to patients, serious adverse event reporting and data collection on peptide use. The trade group's own note on the report says: "The plan has not been announced, there is no announced timeline, and the details could still change."
On 8 October the trade publication Pink Sheet reported that the administration and federal health officials are "finalizing a temporary path for compounding pharmacies to dispense certain peptides", and that "FDA drug center staff said they will not recommend allowing temporary compounding of unapproved peptides", because it "raises patient safety concerns and weakens the drug approval process".
What the official record shows on 14 October
| Claim you may see | What the record shows | Source |
|---|---|---|
| "Peptides are legal now" | No federal document has changed. A Federal Register search for FDA documents since 15 September returns nothing on peptides, and the FDA's press announcements list has no peptide item since then (latest entry 5 October when checked). | Federal Register API, queried 14 Oct 2026; FDA press announcements |
| "The FDA approved a temporary sale plan" | The plan is reported, not announced. Its sources are two unnamed people; HHS did not comment; FDA drug center staff are reported to oppose it. | Washington Post, 7 Oct; Pink Sheet, 8 Oct |
| "Research peptide shops can now sell for human use" | The reported route is state-licensed compounding pharmacies dispensing on a prescription. Nothing reported covers research-use-only vendors, and the FDA's August 2026 warning letters say a research-use label does not change a product's intended use. | Washington Post, 7 Oct; FDA warning letters, 24 Aug 2026 |
| "BPC-157 can be compounded now" | Not yet. The July advisory committee vote for BPC-157 and five others was a recommendation. KFF Health News reported on 13 October that the FDA "has yet to issue a final decision." A substance gets onto the 503A bulks list by rulemaking. | KFF Health News via CNN, 13 Oct; our PCAC vote page |
| "Retatrutide will be part of it" | The FDA's GLP-1 page says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." Lilly plans to file for approval in the first quarter of 2027. | FDA, page current as of 1 Oct 2026; Lilly, 29 Sep 2026 |
| "Ipamorelin and the GHRPs were cleared" | The FDA's own Category 2 page, current as of 22 April 2026, still lists ipamorelin acetate, GHRP-2 and GHRP-6 (nominated under 503B) and kisspeptin-10 (503A) among bulk substances that may present significant safety risks, all added on 29 September 2023. | FDA Category 2 list |
Why the research-use market is not part of this
Everything reported so far describes a pharmacy and prescription pathway. That is a different legal track from the research-use-only market, where vendors sell vials labelled "not for human consumption". The FDA has spent 2026 telling those vendors the label does not work: the 24 August letters to five sellers say that despite the research-use statements on their labeling, evidence from their websites establishes that the products are intended to be drugs for human use.
Courts have gone further. On 18 September a federal jury in New Haven convicted the owner of Pinned Aminos of conspiracy to introduce misbranded or unapproved drugs into interstate commerce. The Justice Department's release says the site's disclaimer "falsely stated that the products for sale were 'intended for laboratory and research use only'" and that the defendants "knew and intended that the drugs they sold were for human use", giving customers "directions on dosage". The full list of 2025 and 2026 actions is in our enforcement tracker.
Which peptides could be covered
Nobody on the record has said. The Post notes that the FDA has been weighing seven peptides its Pharmacy Compounding Advisory Committee considered in July: the committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, and voted against emideltide (DSIP), against the advice of the agency's own scientists. Our page on that vote has every tally. Whether a temporary order would follow that list, cover fewer peptides, or cover others is not known.
Who is for it and who is against it
For: the Alliance for Pharmacy Compounding, which has met the FDA twice on its proposal, and the American Academy of Peptide Medicine, whose chairman Lee Rosebush told the Post: "We would encourage the HHS to use temporary enforcement discretion to allow access to these as soon as possible to help eliminate the gray and black market that currently exists."
Against: FDA drug center staff, per Pink Sheet, and Paul Knoepfler of the University of California at Davis, who told the Post: "I think it just puts people at more risk." Ilisa Bernstein, a former deputy director of the FDA's drug compliance office, sat between the two: she told the Post she has concerns about the lack of safety data, "but it seems inevitable that the floodgates will open, and having appropriate guardrails with the enforcement discretion could help identify safety concerns."
What to watch
- A Federal Register notice from the FDA, or an FDA guidance on enforcement discretion for named peptides. Either would be the first document with legal effect.
- An HHS or White House announcement. Pink Sheet's reporting suggests the announcement may not come from the FDA itself.
- Which peptides are named, and whether the order requires a prescription, a state-licensed 503A pharmacy, adverse event reporting and patient disclosures, as the compounding trade group has asked.
- A proposed rule adding peptides to the 503A bulks list. That is the permanent route, and it requires notice and public comment.
For the full picture of federal and state law today, see are peptides legal in the US, which covers all 50 states.
Questions readers ask
Are peptides legal now?
Nothing has changed in law as of 14 October 2026. The temporary sale plan was reported by the Washington Post on 7 October from two unnamed sources and has not been announced. No FDA notice, guidance or order on peptides has been published. Buying research peptides is not a federal crime for a buyer, but selling unapproved peptides for human use remains illegal.
When will the temporary sale of peptides start?
No date has been given. The Washington Post reported that the plan has not been announced and that timing is unclear. Pink Sheet reported on 8 October that the administration is finalizing it while FDA drug center staff oppose it.
Will research peptide vendors be allowed to sell peptides for human use?
Nothing reported says so. The plan as described runs through state-licensed compounding pharmacies dispensing on a prescription. The FDA's 2026 warning letters say a research-use-only label does not change a product's intended use.
Is BPC-157 legal to compound now?
No. The FDA advisory committee voted in July 2026 to recommend BPC-157 for the 503A bulks list, but that is advice, not a rule. KFF Health News reported on 13 October that the FDA has yet to issue a final decision.
Which peptides would the temporary order cover?
That has not been said. The FDA has been weighing the seven peptides its advisory committee reviewed in July: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon and emideltide (DSIP). The committee backed the first six.
Would retatrutide be included?
The FDA's GLP-1 page says retatrutide and cagrilintide cannot be used in compounding under federal law. Retatrutide is not approved; Eli Lilly plans to file for FDA approval in the first quarter of 2027.
Sources
- Washington Post: The Trump administration is paving way for temporary sale of some unapproved peptides (Rachel Roubein), 7 October 2026
- Same report, full syndicated text (Anchorage Daily News), 8 October 2026
- Alliance for Pharmacy Compounding: Peptide plan reportedly in the works, October 2026
- Pink Sheet: US FDA staff push back against Trump administration interim peptide dispensing order, 8 October 2026
- KFF Health News via CNN: some who have taken hyped, unregulated peptides have regrets, 13 October 2026
- Federal Register API: FDA documents since 15 September 2026 mentioning peptides (0 results), queried 14 October 2026
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2), content current as of 22 April 2026
- FDA warning letter to NuScience Peptides LLC, 24 August 2026
- US Attorney, District of Connecticut: former Connecticut resident guilty of operating websites to illegally sell misbranded and unapproved drugs, 21 September 2026
- Eli Lilly: TRIUMPH-2 results and BLA timing (PR Newswire), 29 September 2026
- reginfo.gov: Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), received by OIRA 14 October 2026, read 20 October 2026